Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.73 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447171 | 0.94 | USP2 (0.80) | USP2KMT2ASMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL21082057 | 0.86 | KMT2A (0.62) | USP2KMT2ASMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL18412261 | 0.85 | KMT2A (0.68) | USP2KMT2ASMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL13100724 | 0.85 | HPGD (0.74) | USP2KMT2ASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL11520668 | 0.85 | USP2 (0.82) | USP2KMT2ASMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL4143110 | 0.84 | KMT2A (1.00) | USP2KMT2ASMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL5363082 | 0.84 | LMNA (0.71) | USP2KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1116738 | 0.82 | KMT2A (0.76) | USP2KMT2ASMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL29634495 | 0.82 | KMT2A (0.76) | USP2KMT2ASMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL14174938 | 0.82 | KMT2A (0.76) | USP2KMT2ASMN1; SMN2MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1243581-B1 | Pyridinium compounds useful for the treatment of AGE-related diseases | TORRENT PHARMACEUTICALS LTD (IN) | 2005-07-13 | — | — | EP | claimed |
| US-6608094-B2 | Breaking preformed AGE | TORRENT PHARMACEUTICALS LTD. (IN) | 2003-08-19 | — | — | US | claimed |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2007-07-19 | — | — | US | disclosed |
| US-7223777-B2 | Compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-05-29 | — | — | US | disclosed |
| EP-1243581-B1 | Pyridinium compounds useful for the treatment of AGE-related diseases | TORRENT PHARMACEUTICALS LTD (IN) | 2005-07-13 | — | — | EP | disclosed |
| EP-1373263-B1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | TORRENT PHARMACEUTICALS LTD (IN) | 2004-10-27 | — | — | EP | disclosed |
| WO-2002085897-A9 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2004-04-01 | — | — | WO | disclosed |
| US-6608094-B2 | Breaking preformed AGE | TORRENT PHARMACEUTICALS LTD. (IN) | 2003-08-19 | — | — | US | disclosed |
| EP-1304101-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | Torrent Pharmaceuticals Ltd (IN) | 2003-04-23 | — | — | EP | disclosed |
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-03-06 | — | — | US | disclosed |
| US-20030032660-A1 | Breaking preformed AGE | TORRENT PHARMACEUTICALS LTD. | 2003-02-13 | — | — | US | disclosed |
| EP-1243581-A1 | Pyridinium compounds useful for the treatment of AGE-related diseases | Torrent Pharmaceuticals Ltd (IN) | 2002-09-25 | — | — | EP | disclosed |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | TORRENT PHARMACEUTICALS LTD. | 2002-08-01 | — | — | US | disclosed |
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2001-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | AGER, GLA, RBP1 | USP2 3868/4885KMT2A 4629/4885SMN1; SMN2 1818/4885 |
| US-20030032660-A1 | Breaking preformed AGE | AGER, GPX1, RBP1 | USP2 4353/4885KMT2A 4457/4885SMN1; SMN2 1658/4885 |
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | USP2 3762/4885KMT2A 3588/4885SMN1; SMN2 4239/4885 |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | PNPO, PRDX5, PLPBP | USP2 3722/4885KMT2A 3459/4885SMN1; SMN2 2608/4885 |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | USP2 3536/4885KMT2A 3499/4885SMN1; SMN2 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.